Results 101 to 110 of about 53,097 (209)

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

Journal of Cutaneous Pathology, Volume 53, Issue 9, Page 767-771, September 2026.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen, Hanadi El Achi, Levani Iashvili, Amer Wahed, Brenda Mai, Jacob Armstrong   +5 more
wiley   +1 more source

Preoperative Avapritinib for Localized PDGFRA‐Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing

Cancer Medicine, Volume 15, Issue 8, August 2026.
In this two‐center retrospective series of eight patients with localized PDGFRA‐mutant gastric GIST treated with preoperative avapritinib, therapy produced substantial antitumor activity, including tumor reduction in 7 of 8 patients and complete or near‐complete pathologic response in all resected patients.
Tannaz Ranjbarian, Mark Antkowiak, Shirley Sarno, Shumei Kato, Adam M. Burgoyne, Skye C. Mayo, Michael C. Heinrich, Paul T. Fanta, Jason K. Sicklick   +8 more
wiley   +1 more source

Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope

International Journal of Laboratory Hematology, EarlyView.
Paige Muir, Mohammad Bahmanyar, Hamish Nicolson, Hayley Merkeley   +3 more
wiley   +1 more source

Acute and Chronic Leukemia in Sub‐Saharan Africa: A Systematic Review

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background The four primary subgroups of leukemia include chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). Very little is known about the regional variation of leukemia and subtypes in sub‐Saharan Africa (SSA).
Allwell A. Ayirebi, Stephen Twumasi, Linda K. Olaga, Benedict Sackey, Daniel N. M. Antonio, Richard O. Ansah, Eugene A. Ansah, John A. Sah, Enoch O. Anto, Yvonne Anang‐Quartey, Antoinette Koomson, Angela Opoku, Godfred A. Donkor, Paulina Duah, Ama G. Boadu, Samuel Essien‐Baidoo, Wina I. O. Boadu, Lilian A. Boateng   +17 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Complex Surgical Decision‐Making in a Nonagenarian With Long‐Term Cancer Survivorship

Journal of the American Geriatrics Society, EarlyView.
Daniel Solomon, Hanoch Kashtan, Lisa Cooper   +2 more
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Imatinib-induced Gynecomastia

Indian Journal of Endocrinology and Metabolism, 2019
Pragya Gupta, Kripa Elizabeth Cherian, Nitin Kapoor, Nambiathayil Aboobacker Fouzia, Thomas Vizhalil Paul   +4 more
openaire   +3 more sources

Clonal and genomic determinants of e1a2 BCR::ABL1 chronic myeloid leukemia: A Fi‐LMC study

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract The rarer p190 (e1a2) transcript in chronic myeloid leukemia (CML) is associated with atypical presentations; yet, its biological basis remains poorly understood. Using a cohort of 60 patients including 42 chronic phase patients age‐matched 1:1 with 42 e13a2/e14a2 patients in the chronic phase, we investigated the clinical, genomic, and clonal
Benjamin Podvin, Olivier Nibourel, Sandrine Hayette, Valérie Coiteux, Rathana Kim, Lucie Rigolot, Stéphanie Dulucq, Augustin Boudry, Geoffrey Pawlak, Wayne‐Corentin Lambert, Pascale Flandrin‐Gresta, Ivan Sloma, Christophe Roumier, Marie Balsat, Sandrine Loron, Chloé Li, Sandrine Geffroy, Jean‐Michel Cayuela, Françoise Huguet, François‐Xavier Mahon, Franck E. Nicolini, Delphine Réa, Claude Preudhomme, Nicolas Duployez, Catherine Roche‐Lestienne, Fi‐LMC group   +25 more
wiley   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

International Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang, Flavia Paternostro, Agnieszka Wozniak, Lore De Cock, Luna De Sutter, Kimberly Verbeeck, Ulla Vanleeuw, Daniël Gorgels, Che‐Jui Lee, Raf Sciot, Patrick Schöffski   +10 more
wiley   +1 more source